Pharma major Dr Reddy's Laboratories on Wednesday said it has received approval from the US health regulator for its new drug application, Elyxyb oralsolution, which is used in the treatment of migraine.
The company has received approval for Elyxyb (celecoxib oral solution 25 mg/mL) from the United States Food and Drug Administration (USFDA), Dr Reddy's said in a filing to BSE.
The product is indicated for the acute treatment of migraine with or without aura in adults, it added.
Elyxyb is the latest product emerging from Dr Reddy's portfolio of successful acute migraine treatments. The company is working to commercialize this product through partners, the filing said.
"We are excited about the approval of Elyxyb. It reaffirms our commitment to innovation and to develop meaningfully differentiated products that address significant unmet needs of patients and physicians, leading to better health outcomes," Dr Reddy's Laboratories CEO Erez Israeli said.
Shares of Dr Reddy's Laboratories closed at Rs3,856.75on BSE, up0.56per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app